



## Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

May 26, 2021

SAN DIEGO--(BUSINESS WIRE)--May 26, 2021-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following investor conferences:

### **Jefferies 2021 Virtual Healthcare Conference**

Fireside Chat Presentation: Wednesday, June 2, 2021 at 1:30 p.m. Eastern Time

### **Goldman Sachs 42<sup>nd</sup> Annual Global Healthcare Conference**

Fireside Chat Presentation: Tuesday, June 8, 2021 at 2:10 p.m. Eastern Time

These conferences will be held virtually. Live webcasts of the presentations will be accessible on the company's website, [www.acadia-pharm.com](http://www.acadia-pharm.com), under the investors section and an archived recording will be available on the website for approximately one month following each presentation.

### *About Acadia Pharmaceuticals*

Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at [www.acadia-pharm.com](http://www.acadia-pharm.com) and follow us on [LinkedIn](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210526005191/en/): <https://www.businesswire.com/news/home/20210526005191/en/>

### *Media Contact:*

Acadia Pharmaceuticals Inc.  
Eric Endicott  
(858) 914-7161  
[media@acadia-pharm.com](mailto:media@acadia-pharm.com)

### *Investor Contact:*

Acadia Pharmaceuticals Inc.  
Mark Johnson, CFA  
(858) 261-2771  
[ir@acadia-pharm.com](mailto:ir@acadia-pharm.com)

Source: Acadia Pharmaceuticals Inc.